ILKAP: A Potential Drug Target and Biomarker for Inflammatory Diseases

Target Name: ILKAP

NCBI ID: G80895

ILKAP

ILKAP: A Potential Drug Target and Biomarker for Inflammatory Diseases

ILKAP (Interleukin-1-Inhibiting Protein) is a protein that is expressed in various tissues throughout the body, including the immune system, and has been shown to play a role in the regulation of inflammation and immune responses. As a result, ILKAP has been identified as a potential drug target and a biomarker for various diseases, including cancer, autoimmune disorders, and inflammatory diseases.

ILKAP is a member of the IL-1 family of cytokines, which are a group of cytoplasmic proteins that play a critical role in the regulation of immune responses and inflammation. The IL-1 family includes several different proteins, including IL-1, IL-2, IL-3, IL-4, IL-5, and IL-6, which are involved in the regulation of different aspects of the immune system, including inflammation, differentiation, and survival.

ILKAP is a 21-kDa protein that is expressed in various tissues throughout the body, including the immune system, skeletal muscles, heart, and brain. It is characterized by a unique N-terminal region that includes a 24 amino acid residue and a 100 amino acid long terminal extension, which is known as an N-tail. The N-tail is thought to play a role in the stability and functions of ILKAP, as well as its interactions with other proteins.

ILKAP has been shown to play a role in the regulation of inflammation and immune responses. For example, studies have shown that ILKAP can inhibit the activity of several pro-inflammatory cytokines, including TNF-alpha, IL-1, and IL-6. This suggests that ILKAP may have a positive effect on the immune system and may be a potential therapeutic target for diseases that are characterized by inflammation and immune dysregulation.

In addition to its potential role in the regulation of inflammation, ILKAP has also been shown to be involved in the regulation of cell survival and metabolism. For example, studies have shown that ILKAP can interact with the protein Bcl-2, which is known to play a role in cell survival and metabolism. This suggests that ILKAP may be involved in the regulation of cell survival and metabolism, and that it may be a potential therapeutic target for diseases that are characterized by cellular dysfunction and survival.

ILKAP has also been shown to be involved in the regulation of cell adhesion and migration. For example, studies have shown that ILKAP can interact with the protein vimentin, which is known to play a role in cell adhesion and migration. This suggests that ILKAP may be involved in the regulation of cell adhesion and migration, and that it may be a potential therapeutic target for diseases that are characterized by these processes.

In conclusion, ILKAP is a protein that is expressed in various tissues throughout the body and is involved in the regulation of inflammation, immune responses, cell survival and metabolism, and cell adhesion and migration. As a result, ILKAP has been identified as a potential drug target and a biomarker for various diseases, including cancer, autoimmune disorders, and inflammatory diseases. Further research is needed to fully understand the role of ILKAP in these processes and to develop effective therapies that target this protein.

Protein Name: ILK Associated Serine/threonine Phosphatase

Functions: Protein phosphatase that may play a role in regulation of cell cycle progression via dephosphorylation of its substrates whose appropriate phosphorylation states might be crucial for cell proliferation. Selectively associates with integrin linked kinase (ILK), to modulate cell adhesion and growth factor signaling. Inhibits the ILK-GSK3B signaling axis and may play an important role in inhibiting oncogenic transformation

The "ILKAP Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ILKAP comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets